Mohamad Mohty

List of Publications by Year
in descending order

244 papers	14,789 citations	18887 64 h-index	29333 108 g-index
245 all docs	245 docs citations	245 times ranked	11316 citing authors

#	Article	IF	Citations
1	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2016, 51, 906-912.	1.3	364
2	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews Clinical Oncology, 2012, 9, 579-590.	12.5	352
3	Acute lymphoblastic leukaemia. Lancet, The, 2020, 395, 1146-1162.	6.3	343
4	Hematopoietic stem cell transplantation in Europe 2014: more than 40â€‰000 transplants annually. Bone Marrow Transplantation, 2016, 51, 786-792.	1.3	338
5	One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematology,the, 2015, 2, e91-e100.	2.2	329
6	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematology,the, 2020, 7, e157-e167.	2.2	319
7	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2017, 52, 811-817.	1.3	310
8	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 2018, 132, 2456-2464.	0.6	301
9	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectivesâ€”a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2015, 50, 781-789.	1.3	294
10	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplantation, 2015, 50, 1037-1056.	1.3	283
11	Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplantation, 2016, 51, 778-785.	1.3	259
12	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood, 2012, 119, 1599-1606.	0.6	254
13	Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. Journal of Clinical Oncology, 2012, 30, 735-741.	0.8	251
14	Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2009, 27, 4570-4577.	0.8	238
15	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	1.7	230
16	Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplantation, 2018, 53, 138-145.	1.3	225
17	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	1.3	221
18	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	1.3	218

#	Article	IF	Citations
19	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	0.6	216
20	Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWPâ€“EBMT analysis on patients with AML in remission. Bone Marrow Transplantation, 2016, 51, 610-611.	1.3	212
21	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia, 2015, 29, 1891-1900.	3.3	199
22	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplantation, 2020, 55, 126-136.	1.3	196
23	Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplantation, 2015, 50, 476-482.	1.3	173
24	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia, 2012, 26, 2462-2468.	3.3	170
25	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2018, 53, 521-534.	1.3	168
26	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation, 2020, 55, 2071-2076.	1.3	163
27	Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplantation, 2016, 51, 1431-1438.	1.3	161
28	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Tâ€™s come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	1.3	147
29	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematology,the, 2019, 6, e573-e584.	2.2	140
30	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 392-399.	1.7	139
31	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1826-1838.	2.0	135
32	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer, 2018, 124, 1428-1437.	2.0	131
33	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 2019, 54, 1575-1585.	1.3	129
34	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. Journal of Clinical Oncology, 2015, 33, 3144-3151.	0.8	119
35	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation, 2022, 57, 1217-1239.	1.3	119
36	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	1.3	117

#	Article	IF	Citations
37	Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biology of Blood and Marrow Transplantation, 2019, 25, 1271-1280.	2.0	116
38	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2012, 30, 2211-2217.	0.8	110
39	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica, 2012, 97, 1666-1673.	1.7	110
40	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood, 2019, 134, 892-899.	0.6	110
41	Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 224-234.	1.7	108
42	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	1.3	106
43	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 1343-1359.	2.0	105
44	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncology, 2018, 4, 1245.	3.4	97
45	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplantation, 2020, 55, 1114-1125.	1.3	97
46	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia, 2014, 28, 779-786.	3.3	95
47	Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia, 2014, 28, 2235-2240.	3.3	93
48	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood, 2015, 126, 2062-2069.	0.6	93
49	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 389-396.	1.3	92
50	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 1142-1152.	2.0	91
51	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	1.7	91
52	Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia, 2019, 33, 2343-2357.	3.3	90
53	How much has allogeneic stem cell transplantâ€“related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Advances, 2020, 4, 6283-6290.	2.5	89
54	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 139-149.	1.7	88

#	Article	IF	Citations
55	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. Leukemia, 2016, 30, 447-455.	3.3	85
56	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€“ a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	1.2	82
57	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biology of Blood and Marrow Transplantation, 2016, 22, 1874-1882.	2.0	78
58	Reducedâ€intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the <scp>A</scp>cute <scp>L</scp>eukemia <scp>W</scp>orking <scp>P</scp>arty of the <scp>E</scp>uropean <scp>G</scp>roup for <scp>B</scp>lood and <scp>M</scp>arrow <scp>T</scp>ransplantation. Cancer, 2015, 121, 1048-1055.	2.0	77
59	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Advances, 2017, 1, 477-485.	2.5	76
60	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2019, 54, 1815-1826.	1.3	75
61	Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer, 2014, 120, 2760-2765.	2.0	73
62	Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 28-34.	2.0	70
63	A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. Journal of Hematology and Oncology, 2017, 10, 24.	6.9	70
64	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Blood, 2020, 136, 39-39.	0.6	70
65	The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia, 2011, 25, 1-6.	3.3	68
66	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplantation, 2016, 51, 351-357.	1.3	68
67	Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica, 2019, 104, 524-532.	1.7	68
68	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. Journal of Hematology and Oncology, 2020, 13, 46.	6.9	68
69	Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transplantation, 2017, 52, 1504-1511.	1.3	63
70	JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplantation, 2017, 52, 1367-1371.	1.3	61
71	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e401-e419.	0.2	61
72	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1975-1983.	2.0	61

#	Article	IF	Citations
73	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	1.3	61
74	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Journal of Hematology and Oncology, 2017, 10, 113.	6.9	60
75	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia, 2016, 30, 2047-2054.	3.3	59
76	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1013-1021.	2.0	59
77	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
78	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2019, 54, 519-530.	1.3	54
79	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. Biology of Blood and Marrow Transplantation, 2015, 21, 489-495.	2.0	53
80	The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer, 2014, 120, 618-623.	2.0	52
81	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. American Journal of Hematology, 2018, 93, 246-253.	2.0	52
82	Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1368-1375.	2.0	51
83	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. Journal of Hematology and Oncology, 2019, 12, 108.	6.9	51
84	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Hematology and Oncology, 2021, 14, 53.	6.9	51
85	Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica, 2013, 98, 172-178.	1.7	50
86	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia, 2020, 34, 283-292.	3.3	48
87	Impact of rabbit ATG-containing myeloablative conditioning regimens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hematological malignancies. Bone Marrow Transplantation, 2015, 50, 45-50.	1.3	47
88	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia, 2019, 33, 2767-2778.	3.3	47
89	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematology,the, 2015, 2, e384-e392.	2.2	46
90	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clinical Hematology International, 2019, 1, 58.	0.7	46

#	Article	IF	Citations
91	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	0.6	45
92	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	3.3	45
93	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	1.3	45
94	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplantation, 2015, 50, 1495-1502.	1.3	44
95	Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Annals of Oncology, 2015, 26, 386-392.	0.6	44
96	Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplantation, 2016, 51, 186-193.	1.3	44
97	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1406-1414.	2.0	44
98	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Journal of Hematology and Oncology, 2020, 13, 87.	6.9	44
99	Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia, 2015, 29, 2375-2381.	3.3	43
100	Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of â©¾10 years. Bone Marrow Transplantation, 2015, 50, 1508-1512.	1.3	43
101	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Journal of Hematology and Oncology, 2017, 10, 20.	6.9	43
102	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. Biology of Blood and Marrow Transplantation, 2012, 18, 314-317.	2.0	42
103	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget, 2016, 7, 43027-43038.	0.8	40
104	Impact of ABO incompatibility on patientsâ€™ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2017, 102, 1066-1074.	1.7	40
105	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. European Journal of Cancer, 2018, 96, 73-81.	1.3	40
106	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research, 2020, 26, 6475-6482.	3.2	40
107	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer Journal, 2020, 10, 26.	2.8	40
108	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget, 2018, 9, 3379-3393.	0.8	40

#	Article	IF	Citations
109	Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institutionâ€™s Three Decade Experience. Biology of Blood and Marrow Transplantation, 2014, 20, 1217-1223.	2.0	39
110	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 751-757.	2.0	39
111	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer Journal, 2019, 9, 88.	2.8	39
112	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 2020, 55, 681-694.	1.3	39
113	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Advances, 2020, 4, 2073-2083.	2.5	39
114	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 278-284.	2.0	38
115	Longâ€term outcome after a treosulfanâ€based conditioning regimen for patients with acute myeloid leukemia: A report from the <scp>A</scp>cute <scp>L</scp>eukemia <scp>W</scp>orking <scp>P</scp>arty of the <scp>E</scp>uropean <scp>S</scp>ociety for <scp>B</scp>lood and <scp>M</scp>arrow <scp>T</scp>ransplantation. Cancer, 2017, 123, 2671-2679.	2.0	37
116	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia, 2019, 33, 230-239.	3.3	36
117	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia, 2020, 34, 128-137.	3.3	36
118	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplantation, 2022, 57, 215-223.	1.3	36
119	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. Journal of Hematology and Oncology, 2016, 9, 89.	6.9	35
120	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. Blood Advances, 2018, 2, 1180-1186.	2.5	35
121	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an <scp>ALWP</scp>/<scp>EBMT</scp> analysis. Journal of Internal Medicine, 2019, 285, 407-418.	2.7	35
122	Thiotepaâ€based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matchedâ€pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2017, 92, 997-1003.	2.0	34
123	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Advances, 2018, 2, 2127-2135.	2.5	34
124	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2019, 54, 1499-1510.	1.3	34
125	High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?. Biology of Blood and Marrow Transplantation, 2015, 21, 620-624.	2.0	33
126	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remissionâ€”Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer, 2017, 123, 824-831.	2.0	32

#	Article	IF	Citations
127	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clinical Cancer Research, 2018, 24, 2794-2803.	3.2	32
128	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 218-224.	1.3	32
129	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. Cancer, 2017, 123, 1965-1970.	2.0	31
130	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2019, 186, 767-776.	1.2	31
131	Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine and Growth Factor Reviews, 2008, 19, 53-63.	3.2	30
132	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer, 2018, 124, 2134-2141.	2.0	30
133	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia, 2020, 34, 2766-2775.	3.3	30
134	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. Haematologica, 2021, 106, 1591-1598.	1.7	29
135	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clinical Cancer Research, 2017, 23, 6478-6486.	3.2	28
136	Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2017, 52, 191-196.	1.3	27
137	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Expert Review of Clinical Pharmacology, 2018, 11, 113-124.	1.3	27
138	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing Tâ€cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (<scp>ALWP</scp>) of the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). British Journal of Haematology, 2018, 183, 411-420.	1.2	27
139	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. Journal of Hematology and Oncology, 2021, 14, 84.	6.9	27
140	Occurrence of graftâ€versusâ€host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. Journal of Internal Medicine, 2018, 283, 178-189.	2.7	26
141	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematology,the, 2021, 8, e205-e215.	2.2	26
142	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia, 2020, 34, 87-99.	3.3	25
143	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 2019, 98, 2389-2398.	0.8	24
144	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1915-1922.	2.0	24

#	Article	IF	Citations
145	The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Annals of Oncology, 2014, 25, 2224-2229.	0.6	23
146	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. British Journal of Haematology, 2018, 181, 86-96.	1.2	23
147	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. European Journal of Haematology, 2019, 103, 107-115.	1.1	23
148	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia, 2019, 33, 1944-1952.	3.3	23
149	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. Journal of Hematology and Oncology, 2019, 12, 68.	6.9	22
150	Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies. Blood Cancer Journal, 2021, 11, 126.	2.8	22
151	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget, 2017, 8, 112972-112979.	0.8	22
152	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 736-744.	2.0	21
153	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Phâ€negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 778-785.	2.0	21
154	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Advances, 2020, 4, 1242-1249.	2.5	21
155	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma â€“ a LWPâ€EBMT study. British Journal of Haematology, 2020, 188, 745-756.	1.2	20
156	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biology of Blood and Marrow Transplantation, 2019, 25, 1890-1897.	2.0	19
157	Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer Journal, 2022, 12, 47.	2.8	19
158	Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 yearâ€old: A study from the acute leukemia working party (<scp>ALWP</scp>) of the <scp>E</scp>uropean group of blood and marrow transplantation (<scp>EBMT</scp>). American Journal of Hematology, 2015, 90, 719-724.	2.0	18
159	Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. American Journal of Hematology, 2017, 92, 653-659.	2.0	18
160	Allogeneic stem cell transplantation benefits for patients â‰¥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2018, 103, 256-265.	1.7	18
161	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. Leukemia, 2021, 35, 585-594.	3.3	18
162	Impact of cyclosporine A concentration on acute graftâ€vsâ€host disease incidence after haploidentical hematopoietic cell transplantation. European Journal of Haematology, 2019, 103, 10-17.	1.1	17

#	Article	IF	Citations
163	FLAMSA-Based Reduced-Intensity Conditioning Versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 2165-2173.	2.0	17
164	Second allogeneic haematopoietic cell transplantation using HLAâ€matched unrelated versus Tâ€cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. British Journal of Haematology, 2021, 193, 592-601.	1.2	17
165	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2251-2260.	2.0	16
166	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. Bone Marrow Transplantation, 2020, 55, 763-772.	1.3	16
167	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEKâ€NUP214 shows a favourable outcome when performed in first complete remission. British Journal of Haematology, 2020, 189, 920-925.	1.2	16
168	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 562-571.	1.3	16
169	Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Cancer Treatment Reviews, 2017, 52, 41-47.	3.4	15
170	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer, 2019, 125, 90-98.	2.0	15
171	Impact of total body irradiationâ€vs chemotherapyâ€based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. American Journal of Hematology, 2020, 95, 1200-1208.	2.0	14
172	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2020, 55, 1763-1772.	1.3	14
173	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. Blood Cancer Journal, 2021, 11, 88.	2.8	14
174	Management of venoâ€occlusive disease: the multidisciplinary approach to care. European Journal of Haematology, 2017, 98, 322-329.	1.1	13
175	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplantation, 2018, 53, 683-691.	1.3	13
176	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor Tâ€cell therapy. British Journal of Haematology, 2021, 193, 1060-1075.	1.2	13
177	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia, 2020, 34, 1144-1153.	3.3	12
178	Impact of detectable measurable residual disease on umbilical cord blood transplantation. American Journal of Hematology, 2020, 95, 1057-1065.	2.0	12
179	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. Bone Marrow Transplantation, 2022, 57, 183-190.	1.3	12
180	Realâ€world treatment patterns and outcomes in nonâ€transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. European Journal of Haematology, 2020, 105, 308-325.	1.1	11

#	Article	IF	Citations
181	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. Bone Marrow Transplantation, 2021, 56, 2454-2463.	1.3	11
182	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. Blood, 2013, 122, 3359-3359.	0.6	11
183	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 2194-2202.	1.3	10
184	Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2. Blood, 2021, 138, 82-82.	0.6	10
185	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transplantation, 2022, 57, 384-390.	1.3	10
186	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncologist, 2015, 20, 50-55.	1.9	9
187	Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3â€•and 6â€•month time points. European Journal of Haematology, 2015, 95, 103-112.	1.1	9
188	Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkinâ€™s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Bone Marrow Transplantation, 2016, 51, 928-932.	1.3	9
189	Highâ€•dose postâ€•transplant cyclophosphamide impairs Î³Î´ Tâ€•cell reconstitution after haploidentical haematopoietic stem cell transplantation using lowâ€•dose antithymocyte globulin and peripheral blood stem cell graft. Clinical and Translational Immunology, 2020, 9, e1171.	1.7	9
190	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 622-634.	1.3	9
191	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 171.e1-171.e8.	0.6	9
192	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 399-406.	1.3	9
193	A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Bone Marrow Transplantation, 2014, 49, 376-381.	1.3	8
194	Antiâ€•thymocyte globulin for graftâ€•versusâ€•host disease prophylaxis in patients with intermediateâ€•or highâ€•risk acute myeloid leukaemia undergoing reducedâ€•intensity conditioning allogeneic stem cell transplantation in first complete remission â€“ a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2019, 184, 643-646.	1.2	8
195	Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 2109-2113.	1.3	8
196	Outcome of Tâ€•cellâ€“replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 2507-2514.	2.0	8
197	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. Bone Marrow Transplantation, 2022, 57, 57-64.	1.3	8
198	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2022, 57, 1556-1563.	1.3	8

#	Article	IF	Citations
199	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Medicine, 2021, 10, 23-33.	1.3	7
200	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. Bone Marrow Transplantation, 2021, 56, 2820-2825.	1.3	7
201	Phase II Prospective Multicentre Study Testing The Efficacy and Safety Of a Clofarabine (Clo), I.v. Busulfan (Bu) and Antithymocyte Globulins (ATG)-Based Reduced-Intensity Conditioning Regimen (RIC) Before Allogeneic Stem Cell Transplantation (allo-SCT) For High-Risk Myelodysplastic Syndrome Or Acute Leukemia: The Cloric Trial. Blood, 2013, 122, 413-413.	0.6	7
202	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplantÂmeasurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia, 2021, 35, 2232-2242.	3.3	6
203	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2021, 56, 2445-2453.	1.3	6
204	Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 729-729.	0.6	6
205	Comparison of fludarabineâ€“melphalan and fludarabineâ€“treosulfan as conditioning prior to allogeneic hematopoietic cell transplantationâ€”a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2022, 57, 1269-1276.	1.3	6
206	Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2014, 49, 950-954.	1.3	5
207	Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function. Bone Marrow Transplantation, 2017, 52, 1049-1050.	1.3	5
208	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 2742-2748.	1.3	5
209	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. Blood, 2019, 134, 775-775.	0.6	5
210	Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT. Blood, 2013, 122, 542-542.	0.6	5
211	Increased Th17/Treg Ratio In Liver Chronic Graft-Versus-Host-Disease. Blood, 2013, 122, 3251-3251.	0.6	5
212	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. Bone Marrow Transplantation, 2022, 57, 1116-1123.	1.3	5
213	Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 614-621.	1.3	4
214	Comparison of non-first-degree related donors and first-degree related donors in haploidentical HSCT: a multi-centre retrospective analysis. Bone Marrow Transplantation, 2021, 56, 2567-2574.	1.3	4
215	Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2012, 120, 356-356.	0.6	4
216	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation, 2022, 57, 572-578.	1.3	4

#	Article	IF	Citations
217	Maintenance after allogeneic HSCT in acute myeloid leukaemia. Lancet Oncology, The, 2020, 21, 1130-1132.	5.1	3
218	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia â€“ a study of the Acute Leukemia Working Party of the EBMT. Leukemia and Lymphoma, 2021, 62, 399-409.	0.6	3
219	Haploidentical transplantation: finally, some light. Blood, 2021, 137, 296-297.	0.6	3
220	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 461-469.	1.3	2
221	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 399-399.	0.6	2
222	Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better. Clinical Hematology International, 2020, 2, 92.	0.7	2
223	The first steps towards a diverse and inclusive EBMT: a position paper. Bone Marrow Transplantation, 2022, 57, 343-346.	1.3	2
224	Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 1951-1954.	0.8	1
225	Treatment of Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome: A Large-Scale Study On Behalf of the Societè•Francìaise De Greffe De Moelle Et De Thèrapie Cellulaire (SFGM-TC). Blood, 2012, 120, 593-593.	0.6	1
226	Different Approaches Of Allogeneic Stem Cell Transplantation For Acute Leukemias In Suzhou (China) Lead To Similar Outcome Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis. Blood, 2013, 122, 2131-2131.	0.6	1
227	Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study. Bone Marrow Transplantation, 2022, , .	1.3	1
228	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 1260-1268.	1.3	1
229	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 0, . .	1.3	1
230	Significance of Busulfan Dose Intensity On Outcomes of Hematopoietic Cell Allografting for AML in Second Complete Remission or Beyond: A Report From the EBMT Acute Leukemia Working Party. Blood, 2012, 120, 1929-1929.	0.6	0
231	Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Blood, 2012, 120, 4153-4153.	0.6	0
232	Long-Lasting HHV-6 Reactivation and Immune Recovery In Adult Long-Survivors After Umbilical Cord Blood (UCB) Allo-SCT: A Comparison With PBSC As Stem-Cell Source. Blood, 2013, 122, 2065-2065.	0.6	0
233	Phenotypic and Functional Characterization Of a Novel Immature Hematopoietic Myeloid Suppressive Progenitor Cells Mobilized By G-CSF. Application To Gvhd Treatment. Blood, 2013, 122, 4476-4476.	0.6	0
234	Autologous Stem Cell Transplantation For Acute Leukemias In Suzhou (China): Similar Outcome In CR1 Patients Compared With European Group For Blood and Marrow Transplantation (EBMT) Results: A Pair-Matched Analysis. Blood, 2013, 122, 5527-5527.	0.6	0

#	Article	IF	Citations
235	Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML). Blood, 2013, 122, 2658-2658.	0.6	0
236	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4364-4364.	0.6	0
237	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 2021-2021.	0.6	0
238	Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic Anemia. Blood, 2016, 128, 5069-5069.	0.6	0
239	Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy). Blood, 2016, 128, 4594-4594.	0.6	0
240	CD34+ Selected Cells "Boost" for Poor Graft Function Post Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 2300-2300.	0.6	0
241	Clono-Specific Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia. Blood, 2016, 128, 1208-1208.	0.6	0
242	Stable Pulmonary Function after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide: A Single Center Experience. Blood, 2020, 136, 30-30.	0.6	0
243	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. Blood, 2020, 136, 26-27.	0.6	0
244	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplantation, 2022, , .	1.3	0